DF-005

DF-005 is an investigational drug candidate being developed by Drug Farm (Shanghai Yaoyuan Biotechnology) for the treatment of Alzheimer's disease. Discovered using the company's proprietary Med-X platform—which combines AI with functional genomics, specifically *piggyBac* transposon-mediated mutagenesis in mice—the drug is currently in the candidate selection stage. While the specific molecular target and modality have not been publicly disclosed, Drug Farm's research focus typically involves modulating innate immune pathways and novel targets identified through their genetic screening technology to address unmet needs in immunology, oncology, and neurodegeneration.